Literature DB >> 19222670

Where are we with the management of hypertension? From science to clinical practice.

Csaba Farsang1, Lisa Naditch-Brule, Angelo Avogaro, Jan Ostergren, Paolo Verdecchia, Aldo Maggioni, Philippe van de Borne, Robert Lins, Alexandre Roca-Cusachs.   

Abstract

The management of elevated blood pressure in patients at high cardiovascular risk is still a subject of debate. The authors review current international guidelines and results of large clinical trials and recent meta-analyses to discuss the different approaches in patients at high risk for cardiovascular events. The different treatment options are considered in view of the modern approach and of the different classes of drugs (diuretics, angiotensin-converting enzyme inhibitors, calcium channel blockers, beta-blockers, and angiotensin II receptor blockers) currently in use. A case report is presented as an illustration of the difficulties related to the management of high blood pressure in patients at increased risk. The benefits of the use of 2 medications that include an inhibitor of the renin-angiotensin-aldosterone system and a calcium channel blocker or a diuretic are discussed. Choosing the proper drugs and correct doses are important considerations for the long-term management of hypertension.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19222670      PMCID: PMC8673101          DOI: 10.1111/j.1751-7176.2008.00066.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  40 in total

Review 1.  A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.

Authors:  Arnfried U Klingbeil; Markus Schneider; Peter Martus; Franz H Messerli; Roland E Schmieder
Journal:  Am J Med       Date:  2003-07       Impact factor: 4.965

2.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

3.  Global challenge for overcoming high blood pressure: Fukuoka Statement, 19 October 2006.

Authors:  Michael H Alderman; Toshio Ogihara
Journal:  J Hypertens       Date:  2007-03       Impact factor: 4.844

4.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Guy De Backer; Anna Dominiczak; Renata Cifkova; Robert Fagard; Giuseppe Germano; Guido Grassi; Anthony M Heagerty; Sverre E Kjeldsen; Stephane Laurent; Krzysztof Narkiewicz; Luis Ruilope; Andrzej Rynkiewicz; Roland E Schmieder; Harry A J Struijker Boudier; Alberto Zanchetti; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Gerasimos Filippatos; Christian Funck-Brentano; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; José Luis Zamorano; Serap Erdine; Wolfgang Kiowski; Enrico Agabiti-Rosei; Ettore Ambrosioni; Lars H Lindholm; Margus Viigimaa; Stamatis Adamopoulos; Enrico Agabiti-Rosei; Ettore Ambrosioni; Vicente Bertomeu; Denis Clement; Serap Erdine; Csaba Farsang; Dan Gaita; Gregory Lip; Jean-Michel Mallion; Athanasios J Manolis; Peter M Nilsson; Eoin O'Brien; Piotr Ponikowski; Josep Redon; Frank Ruschitzka; Juan Tamargo; Pieter van Zwieten; Bernard Waeber; Bryan Williams
Journal:  J Hypertens       Date:  2007-06       Impact factor: 4.844

5.  Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice.

Authors:  Thomas A Burke; Miriam C Sturkenboom; Shou-en Lu; Charles E Wentworth; Yong Lin; George G Rhoads
Journal:  J Hypertens       Date:  2006-06       Impact factor: 4.844

6.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

7.  Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.

Authors:  William J Elliott; Peter M Meyer
Journal:  Lancet       Date:  2007-01-20       Impact factor: 79.321

8.  Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.

Authors:  Peter Sever; Björn Dahlöf; Neil Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre Kjeldsen; Arni Kristinsson; Gordon McInnes; Jesper Mehlsen; Markku Nieminem; Eoin O'Brien; Jan Ostergren
Journal:  Eur Heart J       Date:  2006-12-04       Impact factor: 29.983

9.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.

Authors: 
Journal:  Lancet       Date:  2001-09-29       Impact factor: 79.321

10.  Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study.

Authors:  G de Simone; M H Olsen; K Wachtell; D A Hille; B Dahlöf; H Ibsen; S E Kjeldsen; P A Lyle; R B Devereux
Journal:  J Hum Hypertens       Date:  2007-05-03       Impact factor: 3.012

View more
  7 in total

1.  Junb regulates arterial contraction capacity, cellular contractility, and motility via its target Myl9 in mice.

Authors:  Alexander H Licht; Tobias Nübel; Anja Feldner; Nathalie Jurisch-Yaksi; Marco Marcello; Elena Demicheva; Jun-Hao Hu; Bettina Hartenstein; Hellmut G Augustin; Markus Hecker; Peter Angel; Thomas Korff; Marina Schorpp-Kistner
Journal:  J Clin Invest       Date:  2010-06-14       Impact factor: 14.808

2.  High-throughput metabolomics for evaluating the efficacy and discovering the metabolic mechanism of Luozhen capsules from the excessive liver-fire syndrome of hypertension.

Authors:  Xi-Jun Wang; Xin Gao; Ai-Hua Zhang; Fang-Fang Wu; Guang-Li Yan; Hui Sun
Journal:  RSC Adv       Date:  2019-10-09       Impact factor: 4.036

Review 3.  Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk.

Authors:  Csaba Farsang
Journal:  Vasc Health Risk Manag       Date:  2011-09-26

4.  Hypertension control and cardiometabolic risk: a regional perspective.

Authors:  Martin Thoenes; Peter Bramlage; Sam Zhong; Shuhua Shang; Massimo Volpe; David Spirk
Journal:  Cardiol Res Pract       Date:  2012-01-02       Impact factor: 1.866

5.  Evidence-based chinese medicine for hypertension.

Authors:  Jie Wang; Xingjiang Xiong
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-03       Impact factor: 2.629

6.  Tianma gouteng yin as adjunctive treatment for essential hypertension: a systematic review of randomized controlled trials.

Authors:  Jie Wang; Bo Feng; Xiaochen Yang; Wei Liu; Yongmei Liu; Yun Zhang; Gui Yu; Shengjie Li; Yuqing Zhang; Xingjiang Xiong
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-24       Impact factor: 2.629

7.  Moxibustion (Artemisia Plant at Acupuncture Point) as Alternative Therapy in Hypertension: A Promising Approach.

Authors:  Mohammad Jamshed Siddiqui; Mohamad Fadly Bin Kamarudin; Abdul Kareem Mohammed Al-Shami; Siti Zaiton Mat So'ad; Shazia Qasim Jamshed
Journal:  J Pharm Bioallied Sci       Date:  2017 Oct-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.